- Home
- AMRN
as 01-17-2025 4:00pm EST
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
| Founded: | 1989 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN 2 |
| Market Cap: | 189.2M | IPO Year: | 1993 |
| Target Price: | N/A | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.10 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.43 - $1.37 | Next Earning Date: | 02-27-2025 |
| Revenue: | $241,021,000 | Revenue Growth: | -25.25% |
| Revenue Growth (this year): | -32.98% | Revenue Growth (next year): | -15.55% |
Latest Amarin Corporation plc News
AMRN Breaking Stock News: Dive into AMRN Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Amarin Receives National Reimbursement for VAZKEPA® in Italy
MT Newswires
a month ago
Amarin Names Peter Fishman as CFO
GlobeNewswire
a month ago
Amarin Appoints Peter Fishman Chief Financial Officer
Zacks
2 months ago
After Plunging -19.13% in 4 Weeks, Here's Why the Trend Might Reverse for Amarin (AMRN)
GlobeNewswire
2 months ago
Investigators to Present New REDUCE-IT Subanalysis of VASCEPA®/VAZKEPA® (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association’s (AHA) Annual Scientific Sessions
GuruFocus.com
3 months ago
Amarin Corp PLC (AMRN) Q3 2024 Earnings Call Highlights: Navigating Revenue Declines Amid ...
Zacks
3 months ago
Amarin's Q3 Earnings In Line, Revenues Fall Shy of Estimates
Motley Fool
3 months ago
Amarin Plc (AMRN) Q3 2024 Earnings Call Transcript
Compare AMRN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AMRN Amarin Corporation plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.